Abstract

Ecto-nucleotidase activity is involved in the infection process of Leishmania and various other parasites that enables modulation of host immune responses to promote disease progression. One of the enzymes responsible for this activity is the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase). The enzyme hydrolyzes nucleotides tri- and/or di-phosphate into monophosphate products, which are subsequently hydrolyzed into adenosine. These nucleotides can serve as purinergic signaling molecules involved in diverse cellular processes that govern immune responses. Given the importance of the extracellular metabolism of these nucleotides during intracellular pathogen infections, this study evaluates the role of ecto-nucleotidase activity during Leishmania infantum (L. infantum) infection in human macrophages. E-NTPDase protein expression and activity was evaluated in L. infantum during purine starvation, adenosine-enriched medium, or in the presence of an inhibitor of ecto-nucleotidases. Results show that E-NTPDase is expressed in L. infantum parasites, including on the cell membrane. Furthermore, functional activity of the enzyme was modulated according to the availability of adenosine in the medium. Purine starvation increased the hydrolytic capacity of nucleotides leading to higher infectivity, while growth in adenosine-enriched medium led to lower infectivity. Moreover, inhibiting E-NTPDase function decreased L. infantum infection in macrophages, suggesting the enzyme may serve as a ligand. Taken together, the ability of L. infantum to hydrolyze nucleotides is directly associated with increased infectivity in macrophages.

Highlights

  • Visceral leishmaniasis (VL) is a neglected parasitic disease caused by species of the genus Leishmania, which frequently leads to death if untreated [1, 2]

  • Ecto-Nucleotidase Activity Does Not Differ among L. infantum Isolates

  • Microscopy studies showed that E-NTPDase was present on Infection of Human Macrophages with L. infantum

Read more

Summary

Introduction

Visceral leishmaniasis (VL) is a neglected parasitic disease caused by species of the genus Leishmania, which frequently leads to death if untreated [1, 2]. It is estimated that about 200,000 new cases of VL occur yearly worldwide and that over 90% occur in Bangladesh, Brazil, Ethiopia, India, South Sudan, and Sudan (W.H.O. 2015). VL has a mortality rate of about 5% and has few clinical treatment options [3]. Several factors are determinant for the clinical outcome of VL. Disease severity can range between subclinical and different degree of severity. Several factors involved in early host–parasite interactions and innate immune responses can directly modulate VL severity.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call